All Articles

iRegene Therapeutics hits dual milestones, advancing AI-derived cell therapies for Parkinson's in the US and Multiple System Atrophy in China.

A massive $500 million investment from top private equity firms will accelerate Vero Networks' mission to build high-speed fiber across the U.S.

January data shows a massive jump in corporate financing requests, hinting at a busy year for investment, while the municipal market tells a different story.

With a new CEO known for commercial turnarounds, oneworld signals a strategic push for tech integration, customer value, and competitive growth.

Light Source Communications is building a massive underground dark fiber network to connect St. Louis and Tulsa, powering the AI revolution in the heartland.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

A patent-pending tubing anchor catcher is showing early promise, with reports of 100% production gains by tackling stubborn gas interference issues.

A2Z Cust2Mate reports a pivotal quarter with up to $5.2M in Q4 revenue, as the delivery of over 2,000 AI-powered smart carts begins to pay off.

The global packaging giant's new Rosarito plant leverages nearshoring to offer U.S. winemakers faster, more flexible access to premium screwcap closures.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

A new initiative offers biotech firms free access to advanced epiproteomic analysis, aiming to accelerate the development of next-generation precision medicines.

A new high-grade discovery deep beneath a century-old mine could revive a legendary BC mining district and bolster Canada's critical mineral supply.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

A new three-tube collection system from BD promises to improve accuracy, streamline lab work, and enhance patient safety by reducing sample contamination.

A new platform by Dr. Jess Ingrassellino launches to demystify music tech, empowering a new generation of electric string players and their teachers.

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

A new ready-to-print bio-kit from CollPlant promises to speed up organ engineering and drug discovery while reducing reliance on animal materials.

A new ready-to-print bio-kit from CollPlant promises to speed up organ engineering and drug discovery while reducing reliance on animal materials.